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Abstract
We examined correlations between TGF-B1, TBR-I and
TBR-II, p12CDK2-AP1, p21WAF1, p27KIP1, Smad2, and p-
Smad2 in 125 cases of human oral squamous cell
carcinoma (OSCC) to test the hypothesis that resis-
tance to TGF-B1–induced growth suppression is due
to the disruption of its signaling pathway as a con-
sequence of reduced or lost p12CDK2-AP1. Immuno-
reactivity for TBR-II decreased in OSCC with increasing
disease aggressiveness; however, no differences
were observed for TBR-I and TGF-B1. The expression
of TBR-II significantly correlated with p12CDK2-AP1 and
p27KIP1 (P < .001 andP < .01, respectively). Furthermore,
there was a significant relationship between TBR-II
expression and p-Smad2 (P < .001). The in vivo cor-
relation of the levels of TBR-II, p12CDK2-AP1, and p27KIP1
was confirmed in normal and OSCC cell lines. Addi-
tionally, in vitro analysis of TGF-B1–treated cells
showed that TGF-B1 treatment of normal keratinocytes
suppressed cell growth with upregulation of p-Smad2,
p12CDK2-AP1, and p21WAF1 expression, whereas there
was no effect on OSCC cell lines. These results pro-
vide evidence of a link between a disrupted TGF-B–
Smad signaling pathway and loss of induction of
cell cycle–inhibitory proteins, especially p12CDK2-AP1
in OSCC, which may lead to the resistance of TGF-B1
growth-inhibitory effect on OSCC.
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Introduction
Transforming growth factor-b1 (TGF-b1) is a potent growth
inhibitor of various cell types, including epithelial, endothe-
lial, and hematopoietic cells [1–5]. TGF-b1 signaling is medi-
ated mainly by two serine threonine kinase receptors, TGF-b
receptor I (TbR-I) and TGF-b receptor II (TbR-II), which activate
Smad2/3 and Smad4 transcription factors. The phosphorylation
and activation of these proteins are followed by the formation
of the Smad2/3–Smad4 complex, which translocates to the
nucleus regulating transcriptional responses to TGF-b1 [6–8].
Previous studies have demonstrated that loss of function or
decreased expression of TbR-II is associated with tumor pro-
gression [9,10]. The mechanism of TGF-b1 growth inhibition in
epithelial cells is mediated, in part, by induction of p21WAF1
expression [11]. Recently, TGF-b1 has been found to induce
the expression of a novel cyclin-dependent kinase (CDK) 2 in-
hibitor, p12 CDK2–associating protein 1 (p12CDK2-AP1), in
normal epithelial cells [12]. Mechanistically, p12 plays a role
in TGF-b1–mediated growth suppression by modulating CDK2
activities and pRb phosphorylation [12].
Head and neck cancer affects more than half a million
patients worldwide yearly; despite improvements in surgery,
chemotherapy, and radiation therapy, overall survival has not
improved over the past 30 years [13]. Molecular alterations
frequently associated with head and neck cancer include cyclin
D1 amplification or overexpression, decreased expression of
p53 and pRb, and decreased expression of CDK inhibitors
p27KIP1, p21WAF1, and p16INK4A [14,15]. More recently, de-
creased expression of p12CDK2-AP1 has been associated with
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the development of oral squamous cell carcinoma (OSCC)
[16,17]. p12CDK2-AP1 is an S-phase–associated growth sup-
pressor that binds with DNA polymerase A/primase and/or
CDK2 [18,19]. Studies have shown that p12 is differentially
expressed in normal and tumor oral mucosa, with a reduced
expression in 14.3% of oral dysplasias and in 64% to 72%
of oral cancers, suggesting a potential role for p12CDK2-AP1
as a tumor suppressor in oral keratinocytes [16,17].
A defective TGF-b–Smad signaling pathway, which leads
to loss of response to the proliferation-inhibitory effect of
TGF-b1, has been found in several human cancers, such
as hepatocellular carcinoma, pancreatic cancer, colon carci-
noma, and glioblastoma [20–23]. Recently, mutations of
Smad2 and Smad4 have been found in human head and
neck squamous cell carcinoma cell lines; however, the ex-
pression of TGF-b–Smad signaling proteins in OSCC has
not been reported. In addition, the biologic effects of TGF-b1
on OSCC remain unknown [24]. In the present study, we
tested the hypothesis that resistance to TGF-b1 growth sup-
pression in OSCC is due to the preferential reduction or loss
of p12 expression. We investigated the expression of TGF-
b1, its receptors, and the intracellular TGF-b–Smad signaling
pathway in human OSCC. We also examined whether TGF-
b1 is biologically functional in oral cancer.
Materials and Methods
Tissue Samples
Tissue samples were obtained from 125 previously un-
treated OSCC patients at the Department of Oral and Max-
illofacial Surgery, Ehime University School of Medicine
(Ehime, Japan) from 1991 to 2003. The median age of the
OSCC patients was 68.2 years (SD = 14.1). Twenty-eight
patients were in stage I, 41 patients were in stage II, 23 pa-
tients were in stage III, and 33 patients were in stage IV,
according to tumor–node–metastasis classification [25].
The grade of tumor differentiation was determined according
to the criteria proposed by the World Health Organization
[26]. Histologic mode of invasion was classified according to
the classification of Anneroth et al. [27].
Immunohistochemical Analysis
Tissues were fixed in 10% buffered formalin and embed-
ded in paraffin. Paraffin blocks were cut at 4 mm thickness.
Sections were deparaffinized with xylene and rehydrated in
graded alcohol. Three percent hydrogen peroxide was then
applied to block endogenous peroxidase activity. The sec-
tions were incubated overnight at 4jC with anti-human TGF-
b1 (diluted 1:100; Santa Cruz Biotechnology, Santa Cruz,
CA), TbR-I (diluted 1:100; Santa Cruz Biotechnology), TbR-II
(diluted 1:100; Upstate Biotech, Inc., Lake Placid, NY),
Smad2 (diluted 1:100; Chemicon, Inc., Temecula, CA), p-
Smad2 (diluted 1:100; Santa Cruz Biotechnology), p21WAF1
(diluted 1:50; DAKO, Carpinteria, CA), p27KIP1 (diluted 1:50;
DAKO), and Ki67 (diluted 1:100; Abcam, Inc., Cambridge,
MA). Immunostaining was performed with the Envision sys-
tem (DAKO, Carpinteria, CA) in accordance with the manu-
facturer’s instructions. Peroxidase activity was visualized by
applying diaminobenzidine chromogen containing 0.05% hy-
drogen peroxidase. The sections were then counterstained
with hematoxylin, dehydrated, cleared, and mounted. Nega-
tive control staining was carried out by substituting non-
immune goat or mouse serum for primary antibodies. The
immunoreactivity of antibodies to TGF-b1 and its receptors
was assessed on a visual analogue scale by semiquantifying
cytoplasmic staining. Immunoreactivity was scored as ()
absent, (1+) low (< 25% of positive tumor cells), (2+) moder-
ate (26–75% of positive tumor cells), or (3+) diffuse (> 75% of
positive tumor cells) [27,28]. As for Smad2, p-Smad2,
p21WAF1, p27KIP1, p12CDK2-AP1, and Ki67, nuclear staining of
these antibodies was evaluated by estimating the percent-
age of positive nuclei. OSCCs were assessed based on at
least 10 randomly selected fields. All slideswere interpreted by
two investigators.
Cell Culture
The human immortalized normal oral epithelium cell
lines OKF6 tert-1 and OKF6 tert-2 were gifts from Dr. Jim
Rhienwald (BrighamandWomen’sHospital, HarvardMedical
School, Boston, MA). They were maintained in a serum-free
keratinocyte growth medium (Cell Applications, Inc., San
Diego, CA) containing glutamine, apo-transferrin, bovine
pituitary extract, insulin, human epidermal growth factor,
and hydrocortisone. The human malignant oral epithelium
cell lines SCC4, SCC9, SCC66, UM1, and 1483 were main-
tained in DMEM/F12 supplemented with 10% fetal bovine
serum and 1% PSF. TGF-b1 was obtained from Sigma
(St. Louis, MO). Cells were seeded in six-well plates, TGF-
b1 was added when cells reached 50% confluence, and the
rate of cell duplication was determined by counting cells for
three consecutive days after TGF-b1 treatment.
Protein Preparation and Western Blot Analysis
Subconfluent cells were harvested by trypsinization and
lysed with lysis buffer (50 mM Tris–HCl pH 7.5, 150 mM
NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 mM
b-glycerophosphate, 0.1 mM sodium orthovanadate,
0.1 mM PMSF, 5 mg/ml leupeptin, 0.2% vol/vol Triton X-100,
and 0.5% vol/vol Nonidet P-40). Lysates were incubated for
30 minutes at 4jC and were then centrifuged for 15 minutes
at 4jC. Protein concentrations of lysate were determined
using the Bio-Rad DC protein assay system (Bio-Rad, Her-
cules, CA), with bovine serum albumin as standard. Equal
amounts of proteins were subjected to sodium dodecyl
sulfate polyacrylamide gel electrophoresis (8–15%) and
transferred to PVDF membranes. Membranes were incu-
bated overnight with antibodies specific for p12 (pAb86 rabbit
polyclonal antibody; Strategic Biosciences, Newark, DE),
p27, p21, TbR-I, TbR-II, Smad2, p-Smad2/3 (Santa Cruz
Biotechnology), and b-actin (Sigma), washed, and incubated
with secondary antibody against mouse or rabbit IgG conju-
gated with horseradish peroxidase (Amersham Biosciences,
Piscataway, NJ) for 60 minutes. After washing, visualization
was performed by ECL (Amersham Biosciences) according
to the manufacturer’s recommendations. Band densities
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were measured with UN-SCAN-IT software (Silk Scientific,
Orem, UT).
Statistical Analysis
The correlation between clinicopathological parameters
(i.e., surgical staging) and immunohistochemical analysis
results was assessed, as was the correlation between
TGF-b1, its receptors, and cell cycle–related proteins, and
that between these proteins and the Ki67 labeling index.
Comparative data were analyzed using Mann-Whitney
U test. For all statistical analyses, P < .05 was considered
statistically significant.
Results
Abrogated Expression of TR-II, p-Smad2, and p12CDK2-AP1
in Human OSCC In Vivo
TGF-b1 signaling is mediated mainly by two serine threo-
nine kinase receptors, TbR-I and TbR-II. Loss of function or
decreased expression of TbR-II has been reported in several
tumors; however, the level of TbR-I, TbR-II, and TGF-b1, and
their association with OSCC carcinogenesis and tumor pro-
gression have not been fully described. In this study, we first
examined the expression levels of TGF-b1, TbR-I, and TbR-II
in 125 cases of human OSCC by immunohistochemistry.
Table 1 shows the characteristics of tissue samples used
for the immunohistochemical study. Oral squamous epithe-
lium obtained in surgical procedures not associated with
squamous neoplasia has consistently revealed moderate to
intense homogenous cytoplasmic expression of TGF-b1 and
TGF-b receptors I and II. Homogeneous, moderate, intense
cytoplasmic expression of TGF-b1 and TbR-I was also shown
in OSCC tissues; however, there was significant weak ex-
pression or no expression of TbR-II proteins shown inOSCCs
(Figure 1). According to the progression of clinical stage, the
expression of TbR-II decreased. The intensity of TGF-b1,
TbR-I, and TbR-II expression in different clinical tumor stages
is summarized in Table 2. There was no correlation be-
tween the expression of TGF-b1, TbR-I, or TbR-II and clinico-
pathological parameters such as differentiation and mode of
invasion (data not shown). These results suggest that, in
OSCC, there is a significant progressive loss of expression
of TbR-II, which associates with highly aggressive lesions.
There is no significant loss of expression of TbR-I in OSCC;
TbR-I expression is not directly related to the degree of tumor
differentiation or to local aggressiveness.
Smad2 and Smad4 transcription factors are mediators of
TGF-b1 signaling [6–8]. Phosphorylation activation of
Smad2 is a key step in TGF-b1 signaling for the induction ex-
pression of downstream molecules, such as cell cycle in-
hibitors p21 and p27 [11,29,30]. In our study, Smad2 and
p-Smad2 were shown in the nuclei of the normal epithelium
(Figure 2). Although Smad2 expression was similarly shown
in the nuclei of OSCC, p-Smad2 expression was signifi-
cantly decreased compared to that in the normal epithelium
(Figure 2). Statistical analysis showed that there was a sig-
nificant correlation between the expressions of TbR-II and
p-Smad2 in OSCC (P < .001), whereas there was no cor-
relation between the expressions of TGF-b1, TbR-I, and
p-Smad2 in OSCC (Table 3).
Cell cycle–regulatory proteins are downstreammolecules
of TGF-b–Smad signaling. The growth-inhibitory effect of
TGF-b1 is mediated by inducing the expression of important
cell cycle– inhibitory proteins such as p21WAF1, p12CDK2-AP1,
and p27KIP1 [11,12,29]. Our immunohistochemistry study
showed that there was loss of expression of p12CDK2-AP1
and p21WAF1 in OSCC (Table 4). The mean values of the
labeling indices for p12CDK2-AP1, p21WAF1, p27KIP1, Ki67,
Smad2, and p-Smad2 in OSCC are summarized in Table 4.
A decrease in TbR-II immunoreactivity had a statistically sig-
nificant correlation with decreased p12CDK2-AP1 and p27KIP1
expression (P < .001 and P < .01, respectively) (Table 5). No
correlation between other TGF-b receptors and p21WAF1 was
found. In addition, no correlation between TGF-b1, TbR-I, and
cell cycle–related proteins was observed.
Our immunohistochemistry results showing the loss of
expression of TbR-II, p-Smad2, p21WAF1, and p12CDK2-AP1
in OSCC provide evidence of aberrant TGF-b–Smad path-
way in this human cancer and also indicate the important role
of p21WAF1 and p12CDK2-AP1, potentially inhibiting tumor for-
mation or progression.
Decreased Expression of TR-II, p12, Smad2,
and p-Smad2/3 in Human OSCC Lines In Vitro
The role of the TGF-b–Smad signaling pathway in the
carcinogenesis of head and neck cancer has not been fully
evaluated. To examine this signaling pathway in human
OSCC, we first examined the basal expression levels of
TbR-I, TbR-II, Smad-2, and p-Smad2/3 in human OSCC cell
lines by immunoblotting. Compared with normal keratino-
cytes, an increasing level of TbR-I in OSCC was detected
(Figure 3A); however, the expression of TbR-II was de-
creased in OSCC (Figure 3A). We also detected decreasing
levels ofSmad2andp-Smad2/3 inOSCC(Figure 3B). p27KIP1,
p21WAF1, and p12CDK2-AP1 are negative cell cycle regula-
tors and growth inhibitors, and p21WAF1 and p12CDK2-AP1 are
also implicated to be induced transcriptionally by TGF-b1 in
epithelial cells [11,12]. To study the correlation between TGF-
b–Smad signaling and these growth regulators, we also
Table 1. Characteristics of Tissue Samples Used for Immunohistochemical
Analysis.
Age (years) 23–94
Gender
Male 70
Female 55
T classification
T1 29
T2 64
T3 9
T4 23
N classification
N0 83
N1 27
N2 15
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examined thebasal expression levels of p27KIP1, p21WAF1, and
p12CDK2-AP1. Compared with normal oral keratinocytes,
p12CDK2-AP1 expression decreased in most OSCC cell lines
(Figure 3A); however, decreased expression of p27KIP1 and
p21WAF1 was not consistently found in OSCC cell lines. These
results indicate that a defective TGF-b–Smad signaling path-
way exists in human OSCC and provides a possible link
between loss of p12CDK2-AP1 expression and defective TGF-
b–Smad signaling in OSCC.
Loss of the Growth-Inhibitory Effect of TGF-1
in Human OSCC
TGF-b1 is a potent growth inhibitor of epithelia. To test the
response of human OSCC with a disrupted TGF-b–Smad
pathway to TGF-b1, we compared the growth pattern of
OSCC with that of normal oral keratinocytes after TGF-b1
treatment. Growth suppression was observed in normal
human oral keratinocyte after 24 hours of TGF-b1 exposure
(Figure 4A); however, five malignant SCC cell lines keep
growing even after 72 hours of TGF-b1 treatment (Figure 4,
B–F ). Among the five tumor cell lines, only UM1 showed
partial growth inhibition by TGF-b1 (Figure 4F ). The result
confirmed that human OSCC has significant resistance to
TGF-b1 growth-inhibitory effect.
The key step of TGF-b–Smad signaling ismediated by the
phosphorylation activation of p-Smad2/3 and the induction
Figure 1. Decreased expression of TR-II in human OSCC tissues. The levels of TGF-1 and its associated receptors (TR-I and TR-II) in human OSCC tissues
were compared to those in normal tissues, as described in the Materials and Methods section. The levels of TGF-1 and TR-I did not show any significant
alterations in OSCC, but there was significant reduction of TR-II in OSCCs compared to that in the normal epithelium.
Table 2. Immunohistochemical Analysis of TGF-b1 and Its Receptors in
OSCC Tissues.
Samples OSCC [n (%)]
I (n = 28) II (n = 41) III (n = 23) IV (n = 33)
TGF-b1
0 to 1+ 2 (7.1) 9 (21.9) 3 (13.0) 7 (21.2)
2+ to 3+ 26 (92.9) 32 (78.1) 20 (87.0) 26 (78.8)
TbR-I
0 to 1+ 4 (14.3) 10 (24.4) 7 (30.4) 11 (33.3)
2+ to 3+ 24 (85.7) 31 (75.6) 16 (69.6) 22 (66.7)
TbR-II
0 to 1+ 13 (46.6) 28 (68.3) 18 (78.3) 24 (72.7)
2+ to 3+ 15 (53.6) 13 (31.7) 5 (21.7) 9 (27.3)
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expression of downstream cell cycle inhibitors, such as
p21WAF1 and p12CDK2-AP1, in epithelial cells. To understand
TGF-b1 resistance in OSCC, we further examined the induc-
tion levels of p-Smad2/3, p21WAF1, and p12CDK2-AP1, as well
as the components of the TGF-b–Smad pathway in OSCC
compared with normal oral keratinocytes. Increased levels of
p-Smad2/3, as well as p21WAF1 and p12CDK2-AP1, were found
in normal keratinocytes after 24 hours of TGF-b1 exposure;
however, among the five OSCC lines, p21WAF1 could only be
induced in UM1, and p12CDK2-AP1 induction was found only in
SCC66 (Figure 5, A–D). Besides, a complete failure of
p-Smad2/3 induction was found in all OSCCs examined
(Figure 5, A and B). TbR-I, Smad2, and p27KIP1 levels have
no consistent changes among the fiveOSCCcell lines. These
results strongly suggest that the failure of induction of
p12CDK2-AP1 or p21WAF1 expression is an important event in
the TGF-b1 resistance observed in human OSCC.
Discussion
TGF-b receptors mediate the biologic effects of TGF-b1. The
direct involvement of TbR-I and TbR-II in TGF-b signal trans-
duction suggests that changes in the expression of these
two receptors may lead to loss of TGF-b sensitivity and may
ultimately negate the autocrine growth-regulatory mecha-
nism imposed by TGF-b [31]. TGF-b is a potent regulator of
proliferation, growth, and differentiation in normal squamous
epithelium. TGF-b exerts its antiproliferative effect through
TbR-II. Loss of function or decreased expression of TbR-II
has been reported in several tumors, and it has been de-
scribed as having an association with carcinogenesis and
tumor progression [9,10,32,33]. Recently, Grady et al. [34]
Figure 2. Significant reduction of p-Smad2 in human OSCC tissues. The levels of Smad2 and p-Smad2, known regulators in TGF-1–mediated growth
suppression, were analyzed in human OSCC tissues. Immunohistochemical analysis showed nuclear staining of Smad2 and p-Smad2. There was significant
reduction of p-Smad2 in OSCC, but there was no significant alteration in Smad2.
Table 3. Statistical Analysis of the Correlation of TGF-b1 and Its Receptors
with Smad2 and p-Smad2 in OSCC.
Samples Smad2 P p-Smad2 P
TGF-bI
0 to 1+ (n = 21) 31.7 ± 3.6 NS 16.6 ± 1.7 NS
2+ to 3+ (n = 104) 33.9 ± 1.6 16.8 ± 2.6
TbR-I
0 to 1+ (n = 32) 30.5 ± 2.9 NS 15.3 ± 2.1 NS
2+ to 3+ (n = 93) 34.6 ± 1.7 17.1 ± 1.2
TbR-II
0 to 1+ (n = 83) 22.3 ± 1.8 NS 12.3 ± 1.1 < .001
2+ to 3+ (n = 42) 36.1 ± 2.5 25.2 ± 1.6
NS, not significant.
Table 4. Levels of Known Cell Cycle Regulators and Signaling Molecules in
the TGF-b1–Mediated Pathway in OSCC.
Samples Normal OSCCs
(n = 28)
I (n = 28) II (n = 41) III (n = 23) IV (n = 33)
Ki67 6.3 ± 1.9 26.6 ± 1.8 28.9 ± 1.5 34.2 ± 1.9 36.0 ± 1.7
p12CDK2-AP1 31.3 ± 1.9 17.5 ± 1.8 13.7 ± 1.5 13.6 ± 1.9 14.3 ± 1.6
p21WAF1 25.8 ± 2.3 8.0 ± 1.3 8.9 ± 1.0 7.0 ± 1.4 6.2 ± 1.2
p27KIP1 30.1 ± 3.2 24.3 ± 2.3 25.6 ± 1.9 20.0 ± 2.6 23.1 ± 2.1
Smad2 41.2 ± 3.3 40.0 ± 3.1 32.1 ± 2.6 30.3 ± 3.4 32.0 ± 2.8
p-Smad2 32.8 ± 4.1 24.5 ± 2.1 17.0 ± 1.7 13.5 ± 2.3 12.0 ± 1.9
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reported that mutations in TbR-II coincide with the trans-
formation of benign adenomas to malignant carcinomas in
colon cancers with microsatellite instability. These obser-
vations have led to the hypothesis that escape from TGF-
b–mediated negative growth control is an important aspect
of malignant phenotype in many epithelial neoplasms.
In the present study, we have analyzed the expression of
TGF-b1 and the direct involvement of TbR-I and TbR-II
in OSCC. Our results indicate that expression of TbR-II in-
versely correlates with clinical stages and suggest that ab-
errant TbR-II expression is a contributing factor to OSCC
development. To investigate whether anomalies in TbR-II
expression are specific for this tumor, we have also analyzed
the expression of TbR-I, another component of the TGF-b
signal transduction pathway. The normal squamous epi-
thelium had moderate to high levels of both receptors.
Furthermore, TbR-I was consistently expressed in all tumors
analyzed and in all areas within the tumors. In contrast to
TbR-I, the distribution of TbR-II expression was markedly
Table 5. Statistical Analysis of the Correlation of TGF-b1 and Its Receptors
with Cell Cycle Inhibitors in OSCC.
Samples p12CDK-AP1 P p21CIP/WAF1 P p27KIP1 P
TGF-b1
0 to 1+ (n = 21) 13.9 ± 2.0 NS 5.7 ± 1.4 NS 23.1 ± 1.2 NS
2+ to 3+ (n = 104) 14.7 ± 0.9 7.8 ± 0.6 26.5 ± 2.7
TbR-I
0 to 1+ (n = 32) 13.4 ± 1.7 NS 8.0 ± 0.7 NS 23.6 ± 1.3 NS
2+ to 3+ (n = 93) 15.0 ± 1.0 5.5 ± 1.1 23.8 ± 2.2
TbR-II
0 to 1+ (n = 83) 10.7 ± 0.8 < .001 8.7 ± 1.0 NS 20.2 ± 1.9 < .01
2+ to 3+ (n = 42) 22.2 ± 1.2 6.7 ± 0.7 25.3 ± 1.3
NS, not significant.
Figure 3. Basal expression level of TGF- –Smad signaling proteins in OSCC. (A) Western blot analysis of TR-I, TR-II, p12CDK2-AP1, and p27KIP1 in the normal
oral keratinocytes OKF6 tert1 and OKF6 tert2, as well as in OSCC. Expression of TR-I increased in OSCC compared with that in normal keratinocytes.
Expression of TR-II and p12CDK2-AP1 decreased in OSCC. Multiple bands of TR-II represent different isoforms. (B) Western blot analysis of Smad2 and p-
Smad2/3 in OKF6 tert1 and OSCC shows decreased Smad2 and p-Smad2/3 expression in OSCC. Forty micrograms of total proteins was used for Western blot
analysis. The level of actin is shown as loading control. Protein levels were quantitated by scanning and analysis with UN-SCAN-IT software. Values indicate total
pixel values of a particular protein/actin. The same findings were made from three independent experiments.
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different. In the majority of OSCCs, particularly in infiltrating
regions, TbR-II expression was either markedly reduced or
completely absent. The mechanisms of resistance to the
antiproliferative effects of TGF-b are unknown. However, a
decrease in the number of TbR-II–binding sites has been
associatedwith loss of responsiveness to the TGF-b1 cell line
in the present study. Similar findings were observed in a
number of studies [35–39]. This decrease in TbR-II expres-
sion correlates with tumorigenicity in many cell lines. More-
over, an abnormal TGF-b signal transduction pathway could
contribute to progressive loss of differentiation in carcinomas.
Previous studies revealed cell type–dependent varia-
tions in the effect of TGF-b1 on cell cycle regulators.
p27KIP1 and p21WAF1, both CDK inhibitors, have also been
reported to have an essential role in cell cycle inhibition
induced by TGF-b1 [29,40–42]. Recently, we have sug-
gested that p12CDK2-AP1may play a role in TGF-b1–mediated
growth suppression [12]. This study revealed that TbR-II,
p12CDK2-AP1, p21WAF1, p27KIP1, and p-Smad2 were concor-
dantly decreased, supporting the view that TbR-II and cell
cycle control proteins may play an important role in the
process of cell progression in OSCC. In addition, this result
may provide a link between the effects of growth factor and
cell cycle control in this tumor. Smad proteins play a critical
role in transmitting TGF-b superfamily signals from the cell
surface to the nucleus [43]. By forming a heteromeric com-
plex composed of Smad2/3/4, Smad proteins transduce
TGF-b or activin signals [30]. In the current study, immuno-
histochemistry and Western blot analysis showed the corre-
lation between the abrogated expression of TbR-II, p-Smad2,
Figure 4. Loss of the growth-inhibitory effect of TGF-1 on OSCC. Cells were seeded in six-well plates, 1 ng/ml TGF-1 was added when cells reached 50%
confluence, and the rate of cell duplication was determined by counting cells for three consecutive days after TGF-1 treatment. Values represent cell number, and
data are expressed as the mean and SD of triplicate experiments. (A) Complete growth suppression by 24 hours of TGF-1 exposure in normal keratinocyte
OKF6 tert1. (B–E) Loss of growth suppression even by 72 hours of TGF-1 exposure in OSCC. (F) OSCC UM1 exhibited partial growth inhibition after 48 hours of
TGF-1 exposure.
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and TbR-II, and cell cycle control proteins such as p27KIP1,
p21WAF1, and p12CDK2-AP1. Our data provide evidence of a
disrupted TGF-b–Smad signaling pathway; consequently,
abrogated expression of cell cycle inhibitors such as
p12CDK2-AP1 may lead to loss of response to TGF-b1 growth-
suppressive effects on OSCC.
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